HARBOR研究:SD-OCT分析新生血管性AMD地图样萎缩的危险因素
该研究对HARBOR试验中1097例接受雷珠单抗治疗的nAMD患者进行SD-OCT图像的事后分析,采用CAM标准诊断地图样萎缩,通过多因素比例风险回归识别24个月内MA发生的基线危险因素,并确认既往基于CFP和FA分析发现的危险因素,同时发现新的SD-OCT基线危险因素,而治疗 regimen 和剂量并非危险因素。
要点
- 基线无视网膜下液、存在视网膜内囊肿、3型新生血管和对侧眼萎缩是MA危险因素。
- SD-OCT新发现基线危险因素:中央玻璃膜疣体积较高、脉络膜较薄、新生萎缩、网状假性玻璃膜疣和中央黄斑厚度增加。
- 雷珠单抗治疗方案和剂量水平未发现是MA发展的危险因素。
核心结论
- 在采用CAM萎缩标准的nAMD试验分析中,SD-OCT数据集识别出MA发展的新基线危险因素。
- 既往分析识别的MA危险因素得到确认。
- 每月0.5 mg雷珠单抗治疗未发现是24个月内MA发展的危险因素。
研究设计与样本
- 回顾性、事后分析HARBOR试验(3期、多中心、前瞻性、随机、双盲、阳性对照)的SD-OCT图像。
- 纳入1097例继发于nAMD的中心凹下脉络膜新生血管患者,随机接受雷珠单抗0.5 mg每月、0.5 mg PRN(3次负荷后)、2.0 mg每月或2.0 mg PRN治疗。
- 对941例有24个月随访的可评估SD-OCT黄斑立方扫描,由设盲的读片中心培训评分员每月评估从基线至第24个月。
- 萎缩诊断标准与CAM组提出的一致:光透射入脉络膜、RPE丢失和外层视网膜丢失。
- 采用多因素比例风险回归分析至萎缩发展的时间。
主要发现
- 基线无视网膜下液、存在视网膜内囊肿、存在3型新生血管和存在对侧眼萎缩是MA的基线危险因素。
- SD-OCT分析识别出新的MA基线危险因素:中央玻璃膜疣体积较高、脉络膜厚度较低、存在新生萎缩、存在网状假性玻璃膜疣和中央黄斑厚度增加。
- 雷珠单抗治疗方案和剂量水平未发现是MA发展的危险因素。
关键数值与推荐
- 萎缩诊断标准与CAM组提出的一致:光透射入脉络膜、RPE丢失和外层视网膜丢失。
- 主要结局指标为24个月治疗期间至MA发展的时间所确定的MA危险因素。
- 多因素比例风险回归用于分析至萎缩发展的时间。
临床怎么用
- 对于nAMD患者,基线SD-OCT特征如中央玻璃膜疣体积较高、脉络膜较薄、新生萎缩、网状假性玻璃膜疣和中央黄斑厚度增加可提示MA风险。
- 雷珠单抗治疗方案和剂量选择未显示影响MA发展风险。
局限性
- 本研究为回顾性、事后分析。
- 仅纳入有24个月随访的可评估SD-OCT扫描患者(N=941)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify baseline risk factors for macular atrophy (MA) development in HARBOR via a longitudinal assessment of monthly spectral-domain (SD)-OCT scans. Previous analyses of MA in HARBOR examined data from color fundus photography (CFP) and fluorescein angiography (FA). DESIGN: Retrospective, post hoc analysis of SD-OCT images from HARBOR (ClinicalTrials.gov identifier, NCT00891735), a phase 3, multicenter, prospective, randomized, double-blind, active treatment-controlled clinical trial. PARTICIPANTS: Patients (N = 1097) with subfoveal choroidal neovascularization secondary to neovascular age-related macular degeneration (nAMD) treated with intravitreal ranibizumab 0.5 mg monthly (n = 275), 0.5 mg pro re nata (PRN) after 3 loading doses (n = 275), 2.0 mg monthly (n = 274), or 2.0 mg PRN (n = 273). METHODS: Evaluable SD-OCT macular cube scans from patients with 24 months of follow-up (N = 941) were examined monthly from baseline to month 24 by masked reading center-trained graders. Atrophy diagnosis criteria were consistent with those proposed by the Classification of Atrophy Meetings (CAM) group: hypertransmission of light into the choroid, loss of retinal pigment epithelium, and loss of outer retinal layers. Multivariable proportional hazards regression was performed for time to atrophy development. MAIN OUTCOME MEASURES: Risk factors for MA as determined by time to MA development over 24 months of treatment. RESULTS: Baseline risk factors for MA were confirmed from prior analyses that used CFP and FA data: absence of subretinal fluid, presence of intraretinal cysts, presence of Type 3 neovascularization, and presence of atrophy in the fellow eye. This analysis of SD-OCT data identified new baseline risk factors for MA: higher central drusen volume, lower choroidal thickness, presence of nascent atrophy, presence of reticular pseudodrusen, and increased central foveal thickness. Ranibizumab treatment regimen and dose level were not found to be risk factors for MA development. CONCLUSIONS: In this analysis of a major nAMD trial using CAM atrophy criteria, new baseline risk factors for MA development were identified using an SD-OCT dataset. Risk factors for MA development identified by prior analyses were confirmed. Monthly treatment with ranibizumab 0.5 mg was not found to be a risk factor for MA development over 24 months.
引用
- Sadda SR, Abdelfattah NS, Lei J, et al. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020. PMID: 32402555. doi:10.1016/j.ophtha.2020.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。